Equillium, Inc. (0A4D.L)
| Previous close | 0.8447 |
| Open | 0.7819 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.7819 - 0.7819 |
| 52-week range | 0.4900 - 3.1200 |
| Volume | |
| Avg. volume | 2,796 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2540 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireEquillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
LA JOLLA, Calif., July 18, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced second quarter 2024 estimated ending cash, cash equivalents and short-term investments of approximately $33.3 million, representing an increase of approximately $1.0 million from the end of the first quarter of 2024. The increase is primarily the result of receiving a tax credit of app
Business WireEquillium to Participate in Upcoming Investor Conferences
LA JOLLA, Calif., July 02, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the JonesTrading Healthcare Seaside Summit.
Business WireEquillium to be included in the Russell Microcap® Index
LA JOLLA, Calif., June 12, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.
